Meeting
2012 Genitourinary Cancers Symposium
The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
Authors
Jodi Lyn Layton
Brown University Oncology Group, Providence, RI
Jodi Lyn Layton , Angela Marie Plette , Joseph F. Renzulli II, E. Bradley Miller , Howard Safran , Anthony E. Mega
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
00828308
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 158)
DOI
10.1200/jco.2012.30.5_suppl.158
Abstract #
158
Poster Bd #
D21
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
First Author: Ulrich Krafft
Poster
2019 ASCO Annual Meeting
CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).
First Author: James Andrew Eastham
Poster
2016 Genitourinary Cancers Symposium
Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy.
First Author: Himisha Beltran
Poster
2011 ASCO Annual Meeting
Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer.
First Author: M. Garzotto